Magenta Therapeutics Stock Total Debt
Magenta Therapeutics fundamentals help investors to digest information that contributes to Magenta Therapeutics' financial success or failures. It also enables traders to predict the movement of Magenta Stock. The fundamental analysis module provides a way to measure Magenta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Magenta Therapeutics stock.
Magenta |
Magenta Therapeutics Company Total Debt Analysis
Magenta Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Magenta Therapeutics Total Debt | 29.96 M |
Most of Magenta Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Magenta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Magenta Therapeutics has a Total Debt of 29.96 M. This is 98.91% lower than that of the Biotechnology sector and 90.77% lower than that of the Health Care industry. The total debt for all United States stocks is 99.44% higher than that of the company.
Magenta Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Magenta Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Magenta Therapeutics could also be used in its relative valuation, which is a method of valuing Magenta Therapeutics by comparing valuation metrics of similar companies.Magenta Therapeutics is currently under evaluation in total debt category among its peers.
Magenta Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | (32.66 M) | |||
| Shares Outstanding | 60.66 M | |||
| Shares Owned By Insiders | 2.23 % | |||
| Shares Owned By Institutions | 62.63 % | |||
| Number Of Shares Shorted | 383.03 K | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 0.54 X | |||
| EBITDA | (78.98 M) | |||
| Net Income | (76.46 M) | |||
| Cash And Equivalents | 128.28 M | |||
| Cash Per Share | 2.13 X | |||
| Total Debt | 29.96 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 10.22 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (67.09 M) | |||
| Short Ratio | 1.38 X | |||
| Earnings Per Share | (1.11) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.12 | |||
| Market Capitalization | 45.14 M | |||
| Total Asset | 146.65 M | |||
| Retained Earnings | (402.03 M) | |||
| Working Capital | 101.05 M | |||
| Current Asset | 33.34 M | |||
| Current Liabilities | 3.39 M | |||
| Z Score | -3.88 | |||
| Net Asset | 146.65 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |